These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 8602472)

  • 1. Augmented lung adenocarcinoma cytotoxicity by the combination of a genetically modified anti-Lewis Y antibody and antibodies to complement regulatory proteins.
    Brasoveanu LI; Maio M
    Scand J Immunol; 1996 Mar; 43(3):351-3. PubMed ID: 8602472
    [No Abstract]   [Full Text] [Related]  

  • 2. Augmented lung adenocarcinoma cytotoxicity by the combination of a genetically modified anti-Lewis Y antibody and antibodies to complement regulatory proteins.
    Azuma A; Yamano Y; Yoshimura A; Hibino T; Nishida T; Yagita H; Okumura K; Seya T; Kannagi R; Shibuya M
    Scand J Immunol; 1995 Aug; 42(2):202-8. PubMed ID: 7543216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Construction, production, and characterization of humanized anti-Lewis Y monoclonal antibody 3S193 for targeted immunotherapy of solid tumors.
    Scott AM; Geleick D; Rubira M; Clarke K; Nice EC; Smyth FE; Stockert E; Richards EC; Carr FJ; Harris WJ; Armour KL; Rood J; Kypridis A; Kronina V; Murphy R; Lee FT; Liu Z; Kitamura K; Ritter G; Laughton K; Hoffman E; Burgess AW; Old LJ
    Cancer Res; 2000 Jun; 60(12):3254-61. PubMed ID: 10866319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoclonal antibody against A1 Lewis d antigen produced by the hybridoma immunized with a pulmonary carcinoma.
    Iwaki Y; Kasai MK; Terasaki PI; Bernoco D; Park MS; Cicciarelli J; Heintz R; Saxton RE; Burk MW; Morton DL
    Cancer Res; 1982 Feb; 42(2):409-11. PubMed ID: 7055793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Ch14.18-GM-CSF fusion protein is effective at mediating antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity in vitro.
    Batova A; Kamps A; Gillies SD; Reisfeld RA; Yu AL
    Clin Cancer Res; 1999 Dec; 5(12):4259-63. PubMed ID: 10632368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Lewis-Y carbohydrate antigen is expressed by many human tumors and can serve as a target for genetically redirected T cells despite the presence of soluble antigen in serum.
    Westwood JA; Murray WK; Trivett M; Haynes NM; Solomon B; Mileshkin L; Ball D; Michael M; Burman A; Mayura-Guru P; Trapani JA; Peinert S; Hönemann D; Miles Prince H; Scott AM; Smyth MJ; Darcy PK; Kershaw MH
    J Immunother; 2009 Apr; 32(3):292-301. PubMed ID: 19242371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric and humanized anti-HM1.24 antibodies mediate antibody-dependent cellular cytotoxicity against lung cancer cells.
    Wang W; Nishioka Y; Ozaki S; Jalili A; Verma VK; Hanibuchi M; Abe S; Minakuchi K; Matsumoto T; Sone S
    Lung Cancer; 2009 Jan; 63(1):23-31. PubMed ID: 18524412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59.
    Ziller F; Macor P; Bulla R; Sblattero D; Marzari R; Tedesco F
    Eur J Immunol; 2005 Jul; 35(7):2175-83. PubMed ID: 15971270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved effector functions of a therapeutic monoclonal Lewis Y-specific antibody by glycoform engineering.
    Schuster M; Umana P; Ferrara C; Brünker P; Gerdes C; Waxenecker G; Wiederkum S; Schwager C; Loibner H; Himmler G; Mudde GC
    Cancer Res; 2005 Sep; 65(17):7934-41. PubMed ID: 16140965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Humanized anti-Lewis Y antibodies: in vitro properties and pharmacokinetics in rhesus monkeys.
    Co MS; Baker J; Bednarik K; Janzek E; Neruda W; Mayer P; Plot R; Stumper B; Vasquez M; Queen C; Loibner H
    Cancer Res; 1996 Mar; 56(5):1118-25. PubMed ID: 8640770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor effect of antibody against a SEREX-defined antigen (UOEH-LC-1) on lung cancer xenotransplanted into severe combined immunodeficiency mice.
    Mizukami M; Hanagiri T; Yasuda M; Kuroda K; Shigematsu Y; Baba T; Fukuyama T; Nagata Y; So T; Ichiki Y; Sugaya M; So T; Takenoyama M; Sugio K; Yasumoto K
    Cancer Res; 2007 Sep; 67(17):8351-7. PubMed ID: 17804751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complement dependent cytotoxicity (CDC) activity of a humanized anti Lewis-Y antibody: FACS-based assay versus the 'classical' radioactive method -- qualification, comparison and application of the FACS-based approach.
    Nechansky A; Szolar OH; Siegl P; Zinoecker I; Halanek N; Wiederkum S; Kircheis R
    J Pharm Biomed Anal; 2009 May; 49(4):1014-20. PubMed ID: 19250790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different types of FCgamma-receptors are involved in anti-Lewis Y antibody induced effector functions in vitro.
    Dettke M; Loibner H
    Br J Cancer; 2000 Jan; 82(2):441-5. PubMed ID: 10646902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High expression of glycosphingolipids involved in procoagulant activity of cancer cells.
    Suzuki M; Ando O; Ohta T; Inufusa H; Adachi T; Yasutomi M; Kurimoto M
    Oncol Rep; 1999; 6(1):113-5. PubMed ID: 9864412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complement function in mAb-mediated cancer immunotherapy.
    Gelderman KA; Tomlinson S; Ross GD; Gorter A
    Trends Immunol; 2004 Mar; 25(3):158-64. PubMed ID: 15036044
    [No Abstract]   [Full Text] [Related]  

  • 16. Therapeutic efficacy of anti-Lewis(y) humanized 3S193 radioimmunotherapy in a breast cancer model: enhanced activity when combined with taxol chemotherapy.
    Clarke K; Lee FT; Brechbiel MW; Smyth FE; Old LJ; Scott AM
    Clin Cancer Res; 2000 Sep; 6(9):3621-8. PubMed ID: 10999754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effect of radiation on the expression of tumor-associated antigens of human lung adenocarcinoma cells--an immunologic study using monoclonal antibodies].
    Hareyama M
    Nihon Igaku Hoshasen Gakkai Zasshi; 1988 Dec; 48(12):1553-62. PubMed ID: 3251191
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficient generation of autologous peripheral blood-derived cytotoxic T lymphocytes against poorly immunogenic human tumors using recombinant CD80-adenovirus together with interleukin 12 and interleukin 2.
    Mogi S; Ebata T; Setoguchi Y; Fujime M; Heike Y; Kohsaka T; Yagita H; Okumura K; Azuma M
    Clin Cancer Res; 1998 Mar; 4(3):713-20. PubMed ID: 9533541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-draining lymph nodes of primary lung cancer patients: a potent source of tumor-specific killer cells and dendritic cells.
    Kimura H; Dobrenkov K; Iida T; Suzuki M; Ando S; Yamamoto N
    Anticancer Res; 2005; 25(1A):85-94. PubMed ID: 15816523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ley glycolipid-recognizing monoclonal antibody inhibits procoagulant activity and metastasis of human adenocarcinoma.
    Inufusa H; Adachi T; Kiyokawa T; Nakatani Y; Wakano T; Nakamura M; Okuno K; Shiozaki H; Yamamoto S; Suzuki M; Ando O; Kurimoto M; Miyake M; Yasutomi M
    Int J Oncol; 2001 Nov; 19(5):941-6. PubMed ID: 11604991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.